Health Studies MN

Within 


Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

596 Study Matches

Sorting by: Relevance Distance

Rapid Throughput Screening for Human COVID-19 Infection: A ECG study (RACE)

A Study to Evaluate Rapid Throughput Screening for Human COVID-19 Infection

Elie Berbari
All
18 years and over
This study is NOT accepting healthy volunteers
2020-302666-H01-RST
20-011415
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult males and females age 18 or greater.
  • Undergoing COVID-19 testing by PCR.
  • Willing and able to provide informed consent.
  • Pregnant females (minimal risk study, no risk from ECG).


Exclusion Criteria:

  • Unwilling or unable to provide informed consent.
Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 diagnostic testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Pilot Studies to Reduce COVID19 Infection Risk During Clinical Cardiopulmonary Exercise Testing

A Study to Evaluate Filter Comparison for Reducing COVID-19 Infection Risk

Bruce Johnson
All
18 years to 65 years old
Not Applicable
This study is NOT accepting healthy volunteers
2020-300566-H01-RST
20-004751
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Healthy participants between the age 18-65 years old.
  • Capable of performing submaximal exercise without any known history of heart disease or any past history that would prevent them from performing the exercise and procedures in the study.
  • Women of child bearing age will be required to take a urine pregnancy test.
  • Participants will have to fill out a medical questionnaire.


Exclusion Criteria:

  • Participants less than the age of 18 years.
  • Participants more than the age of 65 years.
  • Participants with compromised cardiovascular or pulmonary function.
  • Unable to pedal an exercise ergometer.
  • Pregnant women as there would be no direct benefit and we do not want to cause undue harm.
Cardiopulmonary exercise test, Other
Coronavirus disease 2019, General infectious diseases
At increased risk of exposure to Severe acute respiratory syndrome coronavirus 2, COVID-19, CPET, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Integrated Biomarker Panel for COVID-19 Infection Risk and Severity Prediction

A Study to Establish An Integrated Biomarker Panel for COVID-19 Infection Risk and Severity Prediction

Alicia Algeciras-Schimnich
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303792-H01-RST
21-001923
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years.​​​​​​​
  • Mayo Clinic patients that have had exposure to SARS-CoV2 virus and/or symptoms related to COVID-19 infection and present to Mayo Clinic for testing.
  • Patients that are willing to consent for a blood draw and provide a blood sample.


Exclusion Criteria:
 

  • Individuals < 18 years  of age.
  • Patients on active treatment for cancer and/or those on immunosuppressants.
  • Pregnant and breast-feeding women.
  • Patients who have had COVID-19 in the past, confirmed in the medical record.
  • Patients who are unable to give written/verbal consent or are unwilling to participate.
Coronavirus disease 2019, General infectious diseases
At risk for infection, COVID-19, COVID-19 diagnostic testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Disorder due to infection, Exposure to 2019 novel coronavirus, Exposure to SARS-CoV-2, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Prospective Observational Study to Correlate BAL CD8+ TRM Cells and Quantitative Lung Fibrosis Scores in Survivors of Moderate-to-Severe COVID-19 Infection (COVID-19 BAL)

A Study to Compare BAL CD8+ TRM Cells and Lung Fibrosis Scores in COVID-19 Infection Survivors

Robert Vassallo
All
60 years to 85 years old
This study is NOT accepting healthy volunteers
2020-300641-H01-RST
20-004911
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria
•COVID-19 Cohort:

  • Patient age: 60-85 years old.
  • SARS-CoV-2 infection confirmed by PCR.
  • Need for hospitalization due to COVID-19 pneumonia.
  • Need for ≥ 2L supplemental oxygen at any point during hospitalization.

Inclusion Criteria
•CONTROL Cohort
:

  • Patient age: 60-85 years old.
  • No pre-existing history of interstitial lung disease or chronic lung disease, except for mild COPD with FEV1 > 80% predicted and FEV1/FVC < 0.7.
  • Absence of lung infiltrate, fever or any signs or infection.
  • Undergoing bronchoscopy for evaluation of lung nodule or adenopathy.

Exclusion Criteria
•COVID-19 and CONTROL Cohorts
:

  • Unable to provide consent to participate in the study.
  • Patient under guardianship or curatorship.
  • Pre-existing interstitial lung disease, pulmonary fibrosis or chronic lung disease, except for mild COPD as outlined in “inclusion criteria.”
  • Active cigarette smoking, vaping or other inhalation use (former smoker providing quit > 90 days prior to admission acceptable).
  • > 20 pack years.
  • Immunocompromised host status due to ongoing therapy with methotrexate, cellcept, azathioprine, prednisone dose > 15 mg daily, rituximab, cyclophosphamide or other biologic agents.
  • Chemotherapy or Radiation therapy in last 2 years.
Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Fibrosis of lung, Patient requires hospitalization, Pneumonia caused by SARS-CoV-2, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Generation of Algorithms that Enable Early Detection of Symptomatic SARS-CoV-2/COVID-19 Infection in High Risk Employees

A Study to Analyze Algorithms for Evaluating Early Detection of SARS-CoV/COVID-19 Infection in Critical Service Employees

Jordan Miller
All
18 years and over
This study is NOT accepting healthy volunteers
2020-102384-P01-RST
20-003412
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Age 18 years or older.
  • Employed at > 0.75 FTE as a healthcare worker, emergency services worker, or critical services employee that has direct contact with patients/customers and cannot abide by social distancing guidelines.
    • Physicians, nurses, allied health, etc.;
    • Police officers, State Patrol, etc.;
    • Cashiers, other positions that can clearly describe how the above criteria place them at high-risk due to regular interactions.
  • Patient is comfortable and willing to interact with a tablet-based interface on a daily basis.


Exclusion Criteria:

  • Under the age of 18 years old.
  • Has previously tested positive or has a pending test for SARS-CoV-2/COVID-19.
  • Is currently undergoing self-quarantine for suspected COVID-19.
  • Works less than 0.75 FTE or cannot clearly articulate the nature of patient/interpersonal interactions that place them at high-risk.
  • Is unable to read and/or unwilling to interact with a tablet-based interface for daily questionnaire.
  • Is unwilling or unable to provide baseline data required for entry into the study.
  • Recent history of unexpected hospitalizations due to a chronic medical condition (e.g., chronic, unstable heart failure).
  • Travel to and from a high-risk area within the past 14 days (e.g., U.S. or international “hot spot”).
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic Rochester, MN — Rochester, MN

Generation of Algorithms for Early Prediction of Aggressive Progression and Hospitalization in Patients Diagnosed with SARS-CoV-2/COVID-19 Infection

A Study to Generate Algorithms for Early Prediction of Aggressive Progression and Hospitalization in Patients Diagnosed with SARS-CoV-2/COVID-19 Infection

Jordan Miller
All
18 years and over
Post Market
This study is NOT accepting healthy volunteers
2020-102394-P01-RST
20-003477
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Over the age of 18 years old.
  • Received a positive test for COVID-19 within the past 48 hours and can provide documentation of the test.
  • Self reports that the patient is comfortable and willing to interact with a tablet-based interface on a daily basis.


Exclusion Criteria:

  • Under the age of 18 years old.
  • Tested positive more than 48 hours prior to contacting study staff or has a pending test for SARS-CoV-2/COVID-19.
  • Cannot confirm a positive test for COVID-19. 
  • Unable to read and/or unwilling to interact with a tablet-based interface for daily questionnaire.
  • Unwilling or unable to provide baseline data required for entry into the study.
  • Currently enrolled in a remote monitoring program via the Center for Connected Care.
  • Any of the following conditions that are contraindicated for use with this device:
    • pacemaker implantation;
    • implantable defibrillator;
    • use of a neuro-stimulator.
Device, Health technology assessment procedure, Research data collection
Coronavirus disease 2019
COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email

A Multicenter, Randomized, Placebo-controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients with Acute, Symptomatic COVID-19 Infection (PREVENT-HD)

A Study to Evaluate Rivaroxaban to Reduce Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients with Acute COVID-19 Infection

Paul Daniels
All
18 years and over
Phase 3
This study is NOT accepting healthy volunteers
2021-303843-P01-RST
21-001915
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:
 

  • Male or female (according to their reproductive organs and functions assigned by chromosomal complement).
  • 18 years of age or older.
  • COVID-19 positive diagnosis by locally obtained viral diagnostic test (e.g., PCR). This may be nasal swab or saliva test or other available technology to demonstrate current infection.
    • Note: this is not an antibody test or serology test that just indicate prior exposure to the disease. In the case of multiple positive COVID-19 PCR tests, only the date of the first test may be used.
  • Confirm that participant is known to health system, with at least 1 contact in EMR prior to screening.
  • Symptoms attributable to COVID-19.
  • Initial treatment plan does not include hospitalization.
  • Presence of at least 1 additional risk factor:
    • Age ≥ 60 years;
    • Prior history of VTE;
    • History of thrombophilia;
    • History of CAD;
    • History of PAD;
    • History of cerebrovascular disease or ischemic stroke;
    • History of cancer (other than basal cell carcinoma);
    • History of diabetes requiring medication;
    • History of heart failure;
    • Body Mass Index ≥ 35 kg/m^2;
    • D-dimer > upper limit of normal for local laboratory (within 2 weeks of the date of the COVID-19 test and prior to randomization).
  • Must provide consent via eConsent indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study, including follow up.
  • Willing and able to adhere to the lifestyle restrictions specified in this protocol.


Exclusion Criteria:

  • Increased risk of bleeding such as:
    • significant bleeding in the last 3 months;
    • active gastroduodenal ulcer in the last 3 months;
    • history of bronchiectasis or pulmonary cavitation;
    • need for dual antiplatelet therapy or anticoagulation;
    • prior intracranial hemorrhage;
    • known severe thrombocytopenia (platelet count <50 x 10^9/L); or
    • active cancer and undergoing treatment.
  • Any illness or condition that in the opinion of the investigator would significantly increase the risk of bleeding (eg recent trauma, recent surgery, severe uncontrolledhypertension, gastrointestinal cancer, renal failure requiring dialysis, severe liver disease, known bleeding diathesis)
  • Known allergies, hypersensitivity, or intolerance to rivaroxaban or its excipients (refer to the IB).
  • Positive COVID-19 antibody or serology test after 2-week period of acute, symptomatic COVID-19 infection.
  • Known diagnosis of triple positive (i.e., positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies) antiphospholipid syndrome.
  • Recently taken or required to take any disallowed therapies.
  • Concomitant Therapy before the planned first dose of study intervention or required during the study. For example, the need for the use of strong cytochrome P450 (CYP) 3A4 inhibitor or inducer per local prescribing information.
  • Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study intervention or is currently enrolled in an experimental, investigational study.
    • Note: participation in an observational registry is allowed.
  • Women who are pregnant or breastfeeding and women of childbearing potential without proper contraceptive measures.
Drug, Other
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Mayo Clinic COVID-19 Pandemic Response Biobank (Prospective) (NA)

COVID-19 Biobank

Andrew Badley
All
Not specified
This study is NOT accepting healthy volunteers
2020-102184-H01-RST
20-003014
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Cohort 1 Inclusion: 

  • Mayo Clinic patients known or suspected to be positive with COVID-19 and/or infection with SARS-CoV-2.
  • Hospitalized at time of identification.
  • All ages will be eligible with appropriate controls for pediatric patients.
  • All racial and ethnic groups are eligible. 
     
    Cohort 2 Inclusion:
  • Mayo Clinic patients known or suspected to be positive with COVID-19 and/or infection with SARS-CoV-2.
  • Not hospitalized at time of identification.
  • All racial and ethnic groups are eligible. 


Exclusion Criteria:

  • None.
Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

COVID-19 Cytokine Assay Validation (COVID-19)

COVID-19 Cytokine Assay

Alicia Algeciras-Schimnich
All
18 years to 60 years old
This study is NOT accepting healthy volunteers
2020-300235-H01-RST
20-004047
Show full eligibility criteria
Hide eligibility criteria

Inclusion Critera:

  • Individuals ≥ 18 and ≤ 60 years of age
  • Has recently been clinically tested for COVID-19 qPCR with either known positive and symptomatic.
  • Patients must be within a radius of Rochester, MN, that allows for reasonable transportation time of the phlebotomist. 


Exclusion Criteria:

  • Patients without prior COVID-19 qPCR results, patients with ambiguous COVID-19 qPCR results.
  • Children under 18 years old or patients over 59 years old.
  • Pregnant women.
  • Patients over 60 years old. 
  • Patients residing beyond a 1 hour drive for the phlebotomist.

 

Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 antibody testing, COVID-19 diagnostic testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Smartphone Enabled Home Screening for COVID-19 Using Electrocardiogram (ECG), Dried Blood Spot (DBS) and Mid-Turbinate NasAL Swab (SIGNAL)

Home Screening for COVID-19

Paul Friedman
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303283-H01-RST
21-000149
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • ≥ 18 years of age.
  • Able to give informed consent; patients will be invited to consent via the portal.
  • Have a US mailing address.  


Exclusion Criteria:

  • Current or previous within 2 months infection to SARS-CoV-2.
  • No compatible smartphone to connect and run the AliveCor system (https://store.alivecor.com/products/kardiamobile).
Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 diagnostic testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

COVID-19 and Acute Kidney Injury (AKI) (COVAKI)

COVID-19 and Acute Renal Failure

Kai Singbartl
All
18 years and over
This study is NOT accepting healthy volunteers
2020-102344-H01-RST
20-003349
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:
 

  • Adult patients, ≥ 18 years of age.
  • Patients testing positive for SARS-CoV-2 and requiring hospitalization at the Mayo Clinic Arizona, Rochester, or Florida campuses.


Exclusion Criteria:

  • Patients < 18 years of age.
  • Patients with pre-existing end-stage renal disease; i.e., need for renal replacement therapy (RRT) prior to index hospitalization.
Acute kidney failure, Acute kidney injury , Coronavirus disease 2019, General infectious diseases
Acute kidney injury due to disease caused by Severe acute respiratory syndrome coronavirus 2, Acute renal failure syndrome, COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Patient requires hospitalization, Respiratory system, Urinary system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Mayo Clinic COVID-19 Virtual Clinic: Post COVID-19 Survey

A Study to Evaluate Post COVID-19 Patients

Ravindra Ganesh
All
18 years and over
This study is NOT accepting healthy volunteers
2020-302902-H01-RST
20-012275
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:
 

  • Mayo Clinic patients with positive COVID-19 test who agreed to follow up through video visit by Mayo COVID-19 Virtual Clinic providers.


Exclusion Criteria:
 

  • Non Mayo Clinic patients.
  • Patients with negative COVID-19 result
Coronavirus disease 2019, General infectious diseases
COVID-19, Chronic post-COVID-19 syndrome, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Post-acute COVID-19, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Mayo Clinic COVID-19 Pandemic Response Biobank of Clinical Residual Samples

COVID-19 Residual Biobank (Enrolling by Invitation Only)

Robin Patel
All
Not specified
This study is NOT accepting healthy volunteers
2020-102269-H01-RST
20-003022
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Mayo Clinic patients diagnosed with or suspected to have COVID-19 (infection with SARS-CoV-2).


Exclusion Criteria:

  • None.
Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 antibody testing, COVID-19 diagnostic testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

ASPIRE II: Acknowledging Disparities In Pregnancy Care During COVID-19 (ASPIRE II)

Acknowledging diSParities In pRegnancy carE during COVID-19

Megan Allyse
Female
18 years and over
This study is NOT accepting healthy volunteers
2020-300469-H01-RST
20-004565
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Female, age 18 or older.
  • Currently pregnant or pregnant within the past 12 months.
  • English or Spanish speaker.


Exclusion Criteria:
 

  • Under the age of 18.
  • Not currently pregnant or pregnant within the past 12 months.
  • Does not speak English or Spanish.
Coronavirus disease 2019, General infectious diseases
Antenatal care status, COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Infection control, Reproductive system, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Cellular Senescence and Its Contribution to COVID-19 Long-Hauler Syndrome

Cellular Senescence and COVID-19 Long-Hauler Syndrome

James Kirkland
All
18 years and over
This study is NOT accepting healthy volunteers
2020-302785-H01-RST
20-011877
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria - Longhaulers Cohort:

Subject population: 100 men and women who have been diagnosed with Post-COVID syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.
  • Positive PCR or antibody test within 18 months of initial study visit.
  • Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.


Exclusion Criteria:

  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.
  • Patient is unfit to participate at the discretion of the Principal Investigator.

Inclusion Criteria - Control Cohort:

Subject population: 50 men and women who have not had a known case of COVID or Longhauler’s syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject or LAR to read and speak the English language.


Exclusion Criteria:

  • Known case of COVID-19.
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.
  • Patient is unfit to participate at the discretion of the Principal Investigator.

Inclusion Criteria - COVID-19 Control Cohort:

Subject population: 50 men and women who have had a known case of COVID, but not Longhauler’s syndrome.

  • Ability to give informed consent or LAR.
  • At least 18 years old.
  • Ability of subject to read and speak the English language.
  • Known case of COVID-19.


Exclusion Criteria:

  • Known Longhauler’s syndrome/Post-COVID
  • Any potential participant who refuses medical record review.
  • Pregnant females.
  • Incarcerated individuals.
  • Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject’s risk by participating in the study.

Eligibility last updated 11/19/21. Questions regarding updates should be directed to the study team contact.

Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Post-acute COVID-19, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Tracking the Recovery of Respiratory Physiology in COVID-19 Patients a Pilot Study (RCR)

Recovery of Respiratory System in COVID-19 Patients

Bruce Johnson
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2021-303578-H01-RST
21-001028
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Have a documented positive qRT-PCR for SARS-CoV-2 confirming prior COVID-19 diagnosis within the last 2-3 months.
  • At least 18 years of age.
  • Female subjects must not be pregnant or trying to become pregnant during the duration of study participation.
  • No known plans to move out of the state, or become unable to return to one of the Mayo Clinic sites for follow-up testing.
  • Must be able to provide clear informed written consent.


Exclusion Criteria:

  • Individuals with pacemakers or other implantable devices that will make interpreting a CT scan challenging.
  • Individuals with major limitations to exercise.
Behavioral
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Mayo Clinic COVID-19 Pandemic Response Stool Biobank (Prospective)

Mayo Clinic COVID-19 Pandemic Response Stool Biobank (Prospective)

Konstantinos Lazaridis
All
18 years and over
This study is NOT accepting healthy volunteers
2020-301022-H01-RST
20-005988
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Mayo Clinic patients with suspected COVID-19 including those who test positive or negative for SARS-CoV-2.
  • All patients 18 years of age and older will be eligible.
  • All racial and ethnic groups are eligible. 


Exclusion Criteria:

  • Individuals under 18 years of age.
Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Human Genomic RNA Phage Display Libraries as a Screening Tool for Identification of COVID-19 Immune Serum Reactive Proteins: means of identifying potential vaccine targets and assays for serologic testing of anti-COVID immunity (COVID19PhageDisplay)

Development of Potential COVID-19 Vaccine and Serological Assay

Svetomir Markovic
All
18 years and over
This study is NOT accepting healthy volunteers
2020-102301-H01-RST
20-003378
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria
•COVID Patient:

  • Adults, age ≥ 18 years old.
  • Confirmed history of COVID-19 viral infection.
  • Now clinically recovered.
  • COVID-19 negative on re-testing or if COVID test is not available, must be symptom-free for 2 weeks.

Exclusion Criteria
•COVID Patient:

  • Post-recovery COVID-19 virus testing remains positive.

Inclusion Criteria 
•Healthy Volunteer:

  • Otherwise healthy adults (age ≥ 18).
  • Not acutely ill.

 

Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 antibody testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Teleworking in the Health Care Industry Due to COVID-19: Employee Satisfaction and Implications

Teleworking in the Health Care Industry Due to COVID-19

Elizabeth Meiners
All
18 years and over
This study is NOT accepting healthy volunteers
2021-306410-H01-RST
21-011499
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Current employees at Mayo Clinic who were transitioned from an in-person work environment to telework due to COVID-19 public health guidelines.


Exclusion Criteria:

  • Employees at Mayo Clinic who were not transitioned from an in-person work environment to telework due to COVID-19 public health guidelines.

Eligibility last updated 11/5/21. Questions regarding updates should be directed to the study team contact.

Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Respiratory system, Teleworker, Works at home
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Dried Blood Spot (DBS) Testing to Assess Post COVID-19 Vaccination Antibody Response (DBS)

Dried Blood Spot COVID-19 Vaccination Response (Enrolling by Invitation Only)

Elitza Theel
All
18 years and over
This study is NOT accepting healthy volunteers
2021-303270-H01-RST
21-000098
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults ≥ 18 years old.
  • DLMP employees who work on-site at SDSC.
  • Plan to complete the two dose SARS-CoV-2 vaccination schedule.


Exclusion Criteria:

  • Children < 18 years old.
  • Subjects who have previously been diagnosed with SARS-CoV-2 infection.
  • Subjects who test SARS-CoV-2 antibody positive on the pre-vaccination sample indicating prior infection.

 

Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 antibody testing, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Immunological consequences of COVID-19 vaccination in patients with Rheumatic Diseases

Immunological Consequences of COVID-19 Vaccination in Patients with Rheumatic Diseases

Hu Zeng
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2021-303399-H01-RST
21-000501
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Rheumatologist confirmed diagnosis of one of the following diagnoses:
    • Systemic lupus erythematosus;
    • Sjogren syndrome;
    • Inflammatory myositis;
    • Psoriatic arthritis;
    • Osteoarthritis;
    • Gout;
    • Ankylosing spondylitis;
    • IBD-related arthritis.


Exclusion Criteria:
 

  • Active infection or untreated malignancy (other than skin cancer) at enrollment.
  • Pregnancy.
Administration of SARS-CoV-2 antigen vaccine, Other, 2019-nCoV vaccination
Arthritis, Coronavirus disease 2019, General infectious diseases, Lupus, Myositis, Osteoarthritis, Psoriatic arthritis, Sjogren's syndrome
COVID-19, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Idiopathic inflammatory myopathy, Musculoskeletal system, Osteoarthritis, Psoriatic arthritis, Respiratory system, Sjögren's syndrome, Systemic lupus erythematosus
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study (NCICOVID)

A Study to Determine the Effects of COVID-19 in Cancer Patients

Mohammad Ranginwala
All
Not specified
This study is NOT accepting healthy volunteers
2020-301371-P01-MAIJ
20-007210
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Step 0 Eligibility Criteria

  • No age restriction.
  • Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
    • Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) or will begin receiving treatment within the next 2 weeks for any CNS or hematologic malignancy or metastatic (Stage IV) solid tumor. Eligible treatment types for hematologic malignancy or metastatic cancer are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, radiation therapy, or targeted radionuclide therapy; or
    • Patient is receiving treatment (defined as current treatment or treatment within the past 6 weeks) or will begin receiving treatment within the next 2 weeks for non-metastatic (Stage I-III) solid tumor. Eligible treatment types for nonmetastatic cancer patients are intravenous chemotherapy, immunotherapy, targeted therapy, radiation therapy, targeted radionuclide therapy, or monoclonal antibody therapy, except trastuzumab/pertuzumab if not accompanied by chemotherapy; or
    • Patient has received an allogenic stem cell transplant or CAR-T cell or other modified cellular therapy at any time; or
    • Patient is currently receiving treatment or prophylaxis for Graft vs. Host Disease.

Testing for SARS CoV-2

  • Patient must have a pending or known positive viral test result for SARS-CoV-2:
    • Patients with prior negative viral SARS-CoV-2 test(s) are eligible if they are being tested again;
    • Patients 18 years of age and older with prior positive viral SARS-CoV-2 test(s) more than 14 days prior to enrollment to Step 1 are not eligible.
    • Patient must be undergoing or have undergone testing for SARS CoV-2:
  • HIV-infected patients are eligible.
  • Patients with CNS metastases are eligible.
  • Co-enrollment on other clinical trials (for cancer or for COVID-19) is allowed.

Step 1 Eligibility Criteria

  • Patient must have a documented positive viral SARS-CoV-2 test:
    • For patients 18 years of age or older, the specimen collection for the positive test must have occurred no earlier than 14 days prior to enrollment to Step 1;
    • For patients under 18 years of age, the specimen collection for the positive test must have occurred after January 31, 2020.
    • The viral test can be either a nucleic acid (PCR) test or an antigen test. Serological or antibody tests are not allowed.
    • The test must have received Emergency Use Approval (EUA) from the FDA and be performed in a CLIA certified lab or patient care setting operating under a CLIA Certificate of Waiver. A full list of tests that have been approved under the EUA can be accessed at:

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19- emergency-use-authorizations-medical-devices/vitro-diagnostics-euas.

  • Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the viral SARS-CoV-2 test.

 

Brain metastasis, Brain tumor, Cancer, Coronavirus disease 2019, General infectious diseases, Graft versus host disease
Allogeneic stem cell transplant, Autologous stem cell transplant, Biological therapy for cancer, Bone marrow transplant, COVID-19, Cancer treatment, Chemotherapy, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Malignant neoplastic disease, Medical Oncology, Nervous system, Radiation therapy, Respiratory system, Targeted drug therapy
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic Health System — Mankato, MN

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study (NCICOVID)

A Study to Determine the Effects of COVID-19 in Cancer Patients

Carola Arndt
All
Not specified
This study is NOT accepting healthy volunteers
2020-301371-P01-RST
20-007210
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

Step 0 Eligibility Criteria

  • No age restriction.
  • Patient must have a prior or current cancer diagnosis (e.g., solid tumor or hematologic malignancy) that fits into any one of the following categories:
    • Patient is receiving active treatment (defined as current treatment or treatment within the past 6 weeks) or will begin receiving treatment within the next 2 weeks for any CNS or hematologic malignancy or metastatic (Stage IV) solid tumor. Eligible treatment types for hematologic malignancy or metastatic cancer are chemotherapy, immunotherapy, monoclonal antibody therapy (e.g., rituximab, trastuzumab, cetuximab), targeted therapy (e.g., BRAF/MEK inhibitor, EGF-R inhibitor), endocrine therapy, radiation therapy, or targeted radionuclide therapy; or
    • Patient is receiving treatment (defined as current treatment or treatment within the past 6 weeks) or will begin receiving treatment within the next 2 weeks for non-metastatic (Stage I-III) solid tumor. Eligible treatment types for nonmetastatic cancer patients are intravenous chemotherapy, immunotherapy, targeted therapy, radiation therapy, targeted radionuclide therapy, or monoclonal antibody therapy, except trastuzumab/pertuzumab if not accompanied by chemotherapy; or
    • Patient has received an allogenic stem cell transplant or CAR-T cell or other modified cellular therapy at any time; or
    • Patient is currently receiving treatment or prophylaxis for Graft vs. Host Disease.

Testing for SARS CoV-2

  • Patient must have a pending or known positive viral test result for SARS-CoV-2:
    • Patients with prior negative viral SARS-CoV-2 test(s) are eligible if they are being tested again;
    • Patients 18 years of age and older with prior positive viral SARS-CoV-2 test(s) more than 14 days prior to enrollment to Step 1 are not eligible.
    • Patient must be undergoing or have undergone testing for SARS CoV-2:
  • HIV-infected patients are eligible.
  • Patients with CNS metastases are eligible.
  • Co-enrollment on other clinical trials (for cancer or for COVID-19) is allowed.

Step 1 Eligibility Criteria

  • Patient must have a documented positive viral SARS-CoV-2 test:
    • For patients 18 years of age or older, the specimen collection for the positive test must have occurred no earlier than 14 days prior to enrollment to Step 1;
    • For patients under 18 years of age, the specimen collection for the positive test must have occurred after January 31, 2020.
    • The viral test can be either a nucleic acid (PCR) test or an antigen test. Serological or antibody tests are not allowed.
    • The test must have received Emergency Use Approval (EUA) from the FDA and be performed in a CLIA certified lab or patient care setting operating under a CLIA Certificate of Waiver. A full list of tests that have been approved under the EUA can be accessed at:

https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19- emergency-use-authorizations-medical-devices/vitro-diagnostics-euas.

  • Any specimen source (e.g., nasopharyngeal swab, oropharyngeal swab, etc.) is allowable for the viral SARS-CoV-2 test.

 

Brain metastasis, Brain tumor, Cancer, Coronavirus disease 2019, General infectious diseases, Graft versus host disease
Allogeneic stem cell transplant, Autologous stem cell transplant, Biological therapy for cancer, Bone marrow transplant, COVID-19, Cancer treatment, Chemotherapy, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Malignant neoplastic disease, Medical Oncology, Nervous system, Radiation therapy, Respiratory system, Targeted drug therapy
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Survey Study to Evaluate Impact of the COVID-19 Pandemic on Inflammatory Bowel Disease at a Multisite Tertiary Institution (IBDCOV20)

A Study to Evaluate Impact of COVID-19 on Inflammatory Bowel Disease

Victor Chedid
All
18 years and over
This study is NOT accepting healthy volunteers
2020-302989-H01-RST
20-012188
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adult patients, ≥ 18 years of age.
  • Diagnosed with Inflammatory Bowel Disease (Crohn's or ulcerative colitis).


Exclusion Criteria:

  • Individuals < 18 years of age.

 

Coronavirus disease 2019, Crohn's disease, General infectious diseases, Inflammatory bowel disease, Ulcerative colitis
COVID-19, Crohn's disease, Digestive system, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Respiratory system, Ulcerative colitis
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTIV-5 / BET)

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

Zelalem Temesgen
All
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
2021-305266-P01-RST
21-007449
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Admitted to a hospital with symptoms suggestive of Coronavirus Disease 2019 (COVID-19) and requires ongoing medical care.
  • Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
  • Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
  • Male or non-pregnant female adult ≥ 18 years of age at time of enrollment.
  • Illness of any duration and has laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay (e.g., Nucleic Acid Amplification Test [NAAT], antigen test) in any respiratory specimen, or saliva 5 times the upper limit of normal.
  • Illness of any duration, and requiring, just prior to randomization, supplemental oxygen (any flow), mechanical ventilation or ECMO (ordinal scale category 5, 6, or 7). 
  • Women of childbearing potential must agree to either abstinence or use at least one acceptable method of contraception from time of screening through 5 months post study IP dosing.
    • Note: acceptable methods include barrier contraceptives (condoms or diaphragms) with spermicide, intrauterine devices (IUDs), hormonal contraceptives, oral contraceptive pills, and surgical sterilization. 
  • Agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of COVID-19 through day 29. 


Exclusion Criteria:

  • ALT or AST > 5 times the upper limit of normal. 
  • Subjects with a low glomerular filtration rate (eGFR), specifically:
    • Subjects with a glomerular filtration rate (eGFR) 20-30 mL/min are excluded unless in the opinion of the principal investigator (PI), the potential benefit of participation outweighs the potential risk of study participation;
    • All subjects with a glomerular filtration rate (eGFR) < 20 mL/min (including hemodialysis and hemofiltration) are excluded.
  • Pregnancy or breast feeding.
  • Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours of enrollment.
  • Allergy to any study medication.
  • Received five or more doses of remdesivir prior to screening.
  • Received two or more doses of > 60 mg of prednisone or equivalent in the 7 days prior to screening.
  • Received small molecule tyrosine kinase inhibitors, including Janus kinase (JAK) inhibitors (e.g., baricitinib, ibrutinib, acalabrutinib, imatinib, gefitinib), in the 4 weeks prior to screening.
  • Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g., tocilizumab, sarilumab, sitlukimab]), or T-cells (e.g., abatacept) in the 4 weeks prior to screening.
  • Received monoclonal antibodies targeting B-cells (e.g., rituximab, and including any targeting multiple cell lines including B-cells) in the 3 months prior to screening.
  • Received granulocyte-macrophage colony-stimulating factor (GM-CSF) agents (e.g., sargramostim) within 2 months prior to screening.
  • Received other immunosuppressants in the 4 weeks prior to screening and in the judgement of the investigator, the risk of immunosuppression with lenzilumab is larger than the risk of Coronavirus Disease 2019 (COVID-19).
  • Received any live vaccine in the 4 weeks prior to screening.
  • Known active tuberculosis.
  • Known history of Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) or untreated hepatitis C (HCV) infection.
  • History of pulmonary alveolar proteinosis (PAP).
  • Has a malignancy currently receiving immunosuppressive chemotherapy, immunodeficiency, uncontrolled opportunistic infection, or uncontrolled cirrhosis.
  • Has a medical condition that could, in the judgment of the investigator, limit the interpretation and generalizability of trial results.
  • Positive test for influenza virus during the current illness (influenza testing is not required by protocol).
  • Previous participation in an ACTIV-5/Big Effect Trial (BET).
Biologic/Vaccine, Drug, Other
Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

Utilization of Pre-procedural Testing of SARS-CoV-2 to Increase Access for Gastrointestinal Endoscopic Procedures (GICS)

A Study to Compare COVID-19 Nasal Testing to Gastric, Bile, or Intestinal Testing

Vinay Chandrasekhara
All
18 years and over
This study is NOT accepting healthy volunteers
2020-300543-H01-RST
20-004721
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Adults > 18 years of age regardless of medical condition.
  • SARS-CoV-2 nasopharyngeal PCR testing prior to gastrointestinal endoscopy as part of routine clinical care. 
  • Undergoing an upper gastrointestinal endoscopic procedure (e.g, EGD, EUS, ERCP, upper enteroscopy), lower endoscopy (colonoscopy, flexible sigmoidoscopy, lower EUS), or ERCP.
  • Ability to understand study procedures and to comply with them for the entire length of the study.

Exclusion Criteria:

  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.  

Coronavirus disease 2019, General infectious diseases
COVID-19, COVID-19 diagnostic testing, Colonoscopy, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Endoscopic ultrasound, Flexible sigmoidoscopy, Respiratory system, Upper endoscopy
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

COVID-FIS: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND EXCESSIVE INFLAMMATORY RESPONSE IN OLDER ADULTS IN NURSING HOMES (COVID-FIS)

A Study to Evaluate Fisetin to Alleviate Dysfunction and Inflammation in COVID-19 Subjects

James Kirkland
All
65 years and over
Phase 2
This study is NOT accepting healthy volunteers
2020-301927-H01-RST
20-008867
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:


1. Men or post-menopausal women age ≥ 65 years.

2. Current nursing home resident.

3. CoV severity of moderate or less OR SpO2 ≥ 85% (on room air or ≤ 2 L of supplemental oxygen at time of enrollment.

4. SARS-CoV-2 infection confirmed by PCR test at Mayo Clinic or other CLIA certified laboratory within 10 days before randomization.

5. Willing and able to provide written informed consent or have a legally authorized representative (LAR) who will provide informed consent.


Exclusion Criteria:


1. Presence of any condition that the Investigator or the subject's attending physician, physician's assistant, or nurse-practitioner believes would put the subject at risk or
would preclude the patient from successfully completing the trial.

2. Pregnancy (note that only post-menopausal women will be enrolled).

3. Total bilirubin > 3 X upper limit of normal or as per clinical judgment.

4. Serum aspartate transaminase (AST) or alanine aminotransferase (ALT) > 4 x the upper limits of normal or as per clinical judgment.

5. Hemoglobin < 7 g/dL; white blood cell count ≤2,000/mm3 (≤ 2.0 x 10^9/L) or ≥25,000/mm^3 (≥25 x 10^9/L); platelet count ≤ 40,000/?L (≤ 40 x 10^9/L); absolute neutrophil count ≤1 x 10^9/L; lymphocyte count < 0.3 x 10^9/L at screening or as per clinical judgment.

6. Unstable (as per clinical judgment) major cardiovascular, renal, endocrine, immunological, or hepatic disorder.

7. eGFR < 25 ml/ min/ 1.73 m^2 or as per clinical judgment.

8. Plasma and/or serum glucose >300 or as per clinical judgment.

9. Human immunodeficiency virus infection.

10. Known active hepatitis B or C infection.

11. Invasive fungal infection.

12. Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites.

13. New/active invasive cancer except non-melanoma skin cancers as per clinical judgment.

14. Known condition associated with major immunodeficiency as per clinical judgment.

15. Known hypersensitivity or allergy to Fisetin.

16. Subjects taking any of the medications listed in Protocol Appendix 1 may participate
if they are otherwise eligible AND the medication can be safely held during the
following times:

- Immediately before the 1st IP administration (Day 0) until at least 10 hours
after the 2nd IP administration (Day 1)

- Immediately before the 3rd IP administration (Day 8) until at least 10 hours
after the 4th IP administration (Day 9)

17. Participation in other clinical trials involving treatment for COVID-19. Note that
institutional standard of care treatment of COVID-19 including glucocorticoids,
hydroxychloroquine, azithromycin, remdesivir, anti-spike antibodies, and/or
convalescent plasma are not excluded from the study.

Drug, Other
Coronavirus disease 2019, General infectious diseases
COVID-19, Disease caused by 2019 novel coronavirus, Fisetin, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

COVFIS-HOME: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND DECREASE COMPLICATIONS IN AT-RISK OUTPATIENTS (COVFIS-HOME)

COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications

Avni Joshi
All
18 years and over
Phase 2
This study is NOT accepting healthy volunteers
2020-302186-H01-RST
20-009705
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Males and females, at least 18 years of age, capable and willing to provide informed consent.
  • Patient must have received a diagnosis of COVID-19 infection within the last 10 days.
  • Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization).
  • Patient must possess at least one of the following high-risk criteria: 70 years or more of age, obesity (BMI ≥ 30 kg/m^2), diabetes mellitus, history of hypertension (systolic blood pressure ≥ 150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease, current or previous smoking), known heart failure, known coronary disease, fever of ≥ 38.4°C within the last 72 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia, or the combination of high neutrophil count and low lymphocyte count.
  • Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g., male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study and for 30 days after study completion.
  • Patient must be able and willing to comply with the requirements of this study protocol.


Exclusion Criteria:

  • Patient currently hospitalized or under immediate consideration for hospitalization.
  • Patient currently in shock or with hemodynamic instability.
  • Patient with severe hepatic disease (as per clinical judgement) and liver enzymes > 2 x the upper limit of normal.
  • Female patient who is pregnant, breast-feeding, or is considering becoming pregnant during the study or for 1 day after the last dose of study medication.
  • Patient currently taking Sirolimus, Tacrolimus, or other mTOR inhibitors for other indications (mainly chronic indications represented by organ transplantation or autoimmune diseases).
  • On Warfarin therapy; subjects taking any of the medications listed in Appendix C may participate if they are otherwise eligible AND the medication can be safely held during the following times:
    • Immediately before the 1st IP administration (Day 0) until at least 10 hours after the 2nd IP administration (Day 1);
    • Immediately before the 3rd IP administration (Day 8) until at least 10 hours after the 4th IP administration (Day 9).
  • Patient with a history of an allergic reaction or significant sensitivity to Fisetin.
  • Patient undergoing chemotherapy for cancer.
  • Patient is considered by the investigator, for any reason, to be an unsuitable study candidate.

Eligibility last updated 8/19/21. Questions regarding updates should be directed to the study team contact.

 

Drug
COPD, Coronary artery disease, Coronavirus disease 2019, Diabetes, General infectious diseases, Heart failure, High blood pressure, Obesity
COVID-19, Cardiovascular system, Disease caused by 2019 novel coronavirus, Disease caused by 2019-nCoV, Endocrine system, Fisetin, Respiratory system
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN

ROR2002: Generation of Algorithms that Enable Early Detection of SARS-CoV-2/COVID-19 Infection and Unrelated Mechanisms of Clinical Decline in High Risk Radiation Oncology Patient Populations (ROR2002)

A Study to Evaluate Early Detection of SARS-CoV-2/COVID-19 in High Risk Radiation Oncology Patients

Jordan Miller
All
18 years and over
This study is NOT accepting healthy volunteers
2020-102396-P01-RST
20-003478
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Over the age of 18 years old.
  • Is currently undergoing clinically-indicated care in the Radiation Oncology Practice or scheduled to start treatment in the Radiation Oncology Practice at Mayo Clinic Rochester.
  • Self reports that the patient is comfortable and willing to interact with a tablet-based interface on a daily basis.
  • Remaining treatment duration of at least 2 weeks.


Exclusion Criteria:

  • Under the age of 18 years old.
  • Has previously tested positive or has a pending test for SARS-CoV-2/COVID-19.
  • Is currently undergoing self-quarantine for suspected COVID-19.
  • Is unable to read and/or unwilling to interact with a tablet-based interface for daily questionnaire.
  • Is unwilling or unable to provide baseline data required for entry into the study.
  • Recent history of unexpected hospitalizations due to a chronic medical condition (e.g., chronic, unstable heart failure).
  • Currently enrolled in the Remote monitoring program via Center for Connected Care.
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic Rochester, MN — Rochester, MN

Impact of Health Coaching on Outcomes of Post-COVID Syndrome: A Pilot Study (HC_PCOCC)

Health Coaching Post COVID

Ravindra Ganesh
All
18 years and over
Not Applicable
This study is NOT accepting healthy volunteers
2021-304525-H01-RST
21-004509
Show full eligibility criteria
Hide eligibility criteria

Inclusion Criteria:

  • Male or female, ≥ 18 years of age.
  • Prior positive SARS-CoV-2 testing.
  • Persistent symptoms meeting diagnosis of PoCoS.
  • Access to electronic platform (email, device, internet).
  • English speaking.


Exclusion Criteria:

  • Individual, < 18 years of age.
  • Acute COVID infection.
  • No prior positive COVID testing.

 

Behavioral, Health coaching of subject
Coronavirus disease 2019, General infectious diseases
COVID-19, Chronic post-COVID-19 syndrome, Disease caused by 2019 novel coronavirus, Post-acute COVID-19, Respiratory system, Wellness coaching
I'm interested
Share via email
Show 1 location
Hide all locations

Location Contacts
Mayo Clinic — Rochester, MN